Product Information

ROFLUMILAST 250 MCG TABLET is a generic product labeled by Camber Pharmaceuticals Inc., priced at $1.5343 per EA under NDC 31722067636. Its NADAC has been published 181 times since Jun 7, 2023.

FDA first approved this application on Nov 23, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

ROFLUMILAST 250 MCG TABLET

Roflumilast
$1.5343per EA

Strength

250 ug/1

NDC

31722067636

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

ROFLUMILAST

Approval Type

Generic (ANDA)

FDA Application

ANDA208213

FDA Approved

11/23/2018

TE Code

AB

On Market Since

4/18/2023

Pharmacological Classes

Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 Inhibitors

Price Statistics

The NADAC for ROFLUMILAST 250 MCG TABLET has been published 181 times since Jun 7, 2023, and over the history we have for it it has declined 86.8%. The table below summarizes its recorded NADAC range and movement.

Current price$1.5343 per EA
All-time high$11.6579 (Jul 12, 2023)
All-time low$1.5343 (Nov 18, 2026)
52-week high$2.3109
52-week low$1.5343
Median price$2.3559
Average price$2.9585
Largest weekly change+63.4% (Aug 21, 2024)
Weeks tracked181
Tracking sinceJun 7, 2023

Price History

1W

-15.0%

1M

-22.6%

3M

-23.2%

6M

-21.3%

1Y

-33.6%

3Y

-56.2%

5Y

N/A

All

-86.8%

Generic Alternatives

The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of ROFLUMILAST 250 MCG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for ROFLUMILAST 250 MCG TABLET, manufactured by Camber Pharmaceuticals Inc., is $1.5343 per EA (NDC 31722067636), effective Nov 18, 2026.

How has the price of ROFLUMILAST 250 MCG TABLET changed over time?

Over the history we have for it, the NADAC for ROFLUMILAST 250 MCG TABLET has declined 86.8%. It has been tracked across 181 weekly CMS publications since Jun 7, 2023.

What are the highest and lowest recorded NADAC prices for ROFLUMILAST 250 MCG TABLET?

Since Jun 7, 2023, the NADAC for ROFLUMILAST 250 MCG TABLET has ranged from a low of $1.5343 (Nov 18, 2026) to a high of $11.6579 (Jul 12, 2023), with a median of $2.3559 per EA.

Are there cheaper alternatives to ROFLUMILAST 250 MCG TABLET?

5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ROFLUMILAST 250 MCG TABLET in a comparable dosage form, but none are currently priced below it.

Who manufactures ROFLUMILAST 250 MCG TABLET?

ROFLUMILAST 250 MCG TABLET (NDC 31722067636) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.